Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
Public ClinicalTrials.gov record NCT00103727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia
Study identification
- NCT ID
- NCT00103727
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 282 participants
Conditions and interventions
Conditions
Interventions
- Talnetant Drug
- placebo Other
- risperidone Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2004
- Primary completion
- Sep 30, 2005
- Completion
- Sep 30, 2005
- Last update posted
- Apr 28, 2015
2004 – 2005
United States locations
- U.S. sites
- 22
- U.S. states
- 11
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Little Rock | Arkansas | 72201 | — |
| GSK Investigational Site | Anaheim | California | 92805 | — |
| GSK Investigational Site | Cerritos | California | 90703 | — |
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | Glendale | California | 91206 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | Pico Rivera | California | 90660 | — |
| GSK Investigational Site | Rosemead | California | 91770 | — |
| GSK Investigational Site | San Diego | California | 92123 | — |
| GSK Investigational Site | San Diego | California | 92126 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| GSK Investigational Site | North Miami | Florida | 33161 | — |
| GSK Investigational Site | Atlanta | Georgia | 30308 | — |
| GSK Investigational Site | Oak Brook | Illinois | 60523 | — |
| GSK Investigational Site | St Louis | Missouri | 63118 | — |
| GSK Investigational Site | Clementon | New Jersey | 08021 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19131 | — |
| GSK Investigational Site | Austin | Texas | 78756 | — |
| GSK Investigational Site | Irving | Texas | 75062 | — |
| GSK Investigational Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00103727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2015 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00103727 live on ClinicalTrials.gov.